dalteparin and Stroke studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

Excerpt	Relevance	Reference
"Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy."	9.22	Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016)
"The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease."	9.16	Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012)
"Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy."	9.13	Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008)
"Extended dalteparin treatment for up to 45 days is effective and safe as a bridging therapy for patients with unstable coronary artery disease awaiting revascularization."	9.10	Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002)
"Treatment with tinzaparin, at high or medium dose, within 48 h of acute ischaemic stroke did not improve functional outcome compared with aspirin."	9.09	Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001)
"The present data do not provide any evidence that LMWH is superior to aspirin for the treatment of acute ischaemic stroke in patients with atrial fibrillation."	9.09	Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
" The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)."	7.85	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). ( Arbetter, D; Bandman, O; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S, 2017)
" dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH."	6.70	Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002)
"Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio."	6.61	Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019)
"The mainstay of treatment for unstable coronary artery disease (UCAD) currently consists of antithrombotic therapy with aspirin plus unfractionated heparin (UFH), together with anti-ischemic treatment with beta blockers and nitrates."	6.19	Long-term management--the way forward? ( Wallentin, L, 2000)
"BRIDGE was a randomized, double-blind, placebo-controlled trial of bridge therapy with dalteparin 100 IU/kg twice daily in patients with atrial fibrillation requiring warfarin interruption."	5.27	Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. ( Clark, NP; Douketis, JD; Hasselblad, V; Kindzelski, AL; Ortel, TL; Schulman, S, 2018)
"Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy."	5.22	Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016)
"We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months."	5.19	Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014)
"The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease."	5.16	Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012)
"TAIST was a randomized controlled trial assessing 10 days of treatment with tinzaparin versus aspirin in 1489 patients with acute ischemic stroke (<48 hr) with admission BP of	5.14	The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). ( Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Gray, LJ; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2009)
" We examined the incidence and outcomes after bleeding in 20 078 patients with acute coronary syndromes (ACS) enrolled in the OASIS-5 trial who were treated with fondaparinux or the low-molecular weight heparin, enoxaparin."	5.14	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Fox, KA; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2009)
"The analyses used data from the Tinzapararin in Acute Ischaemic Stroke Trial, a randomized controlled trial assessing tinzaparin (low molecular weight heparin) versus aspirin in 1484 patients with acute ischemic stroke."	5.14	Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. ( Bath, PM; Christensen, H; De Deyn, P; England, TJ; Geeganage, C; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2010)
"Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy."	5.13	Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008)
"Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity."	5.12	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Pogue, J; Wallentin, L; Yusuf, S, 2006)
"TAIST was a randomized, controlled trial assessing the safety and efficacy of tinzaparin versus aspirin in 1484 patients with acute ischemic stroke."	5.12	Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). ( Bath, PM; Boysen, G; De Deyn, PP; Gray, LJ; Leys, D; O'Neill, D; Ringelstein, EB; Sprigg, N, 2007)
"Thirty-three patients with atrial fibrillation were randomly treated either with OAT (warfarin 10, 7."	5.10	Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation? ( Husted, SE; Lassen, JF; Zeuthen, EL, 2003)
"Extended dalteparin treatment for up to 45 days is effective and safe as a bridging therapy for patients with unstable coronary artery disease awaiting revascularization."	5.10	Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002)
"The present data do not provide any evidence that LMWH is superior to aspirin for the treatment of acute ischaemic stroke in patients with atrial fibrillation."	5.09	Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
"Treatment with tinzaparin, at high or medium dose, within 48 h of acute ischaemic stroke did not improve functional outcome compared with aspirin."	5.09	Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001)
"In the pooled analysis of individual patient data comparing dabigatran with warfarin (SPAF and venous thromboembolism treatment indications), myocardial infarction occurrence favored warfarin (odds ratio [OR] 1."	4.89	Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. ( Clemens, A; Fraessdorf, M; Friedman, J, 2013)
" High-dose atorvastatin reduces recurrent stroke in patients with recent stroke, but probably slightly increases central nervous system hemorrhage (SPARCL)."	4.84	What's new in stroke? The top 10 studies of 2006-2008. Part II. ( Hart, RG, 2008)
" We included patients aged ≥ 18 years with incident stroke diagnosis and assessed prophylactic use of anticoagulants in the 30 days following hospital discharge including low-molecular-weight heparin (enoxaparin ≤40 mg/day, dalteparin ≤5000 IU/day), unfractionated heparin ≤5000 IU/ twice daily or 3 times a day, apixaban 2."	4.12	Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019. ( Cuker, A; Dawwas, GK; Hennessy, S; Rothstein, A, 2022)
"ENSURE-AF (NCT02072434) assessed therapy with edoxaban vs enoxaparin-warfarin in patients with nonvalvular atrial fibrillation (AF) undergoing elective electrical cardioversion (ECV)."	3.96	Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. ( De Caterina, R; Goette, A; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Merino, JL, 2020)
" The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)."	3.85	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). ( Arbetter, D; Bandman, O; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S, 2017)
"Over 2 million patients in North America are on warfarin anticoagulation therapy for prevention of thromboembolism."	3.73	Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. ( Ahmed, M; Bragg, L; Brotman, DJ; Jaffer, AK; Klein, A; Qadeer, MA; Seshadri, N, 2005)
"The results show that the treatment with heparin and nadroparin is safe and effective."	2.82	The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study. ( Dluha, J; Dusenka, R; Kalmarova, K; Kantorova, E; Kurca, E; Nosal, V; Sivak, S; Turcanova Koprusakova, M, 2016)
"Internal carotid artery stenosis was asymptomatic in 55% and symptomatic in 45%."	2.73	Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. ( Assadian, A; Hagmüller, GW; Hübl, W; Klingler, A; Knöbl, P; Pfaffelmeyer, N; Senekowitsch, C, 2008)
"Minor bleeding was defined as hematoma that did not require intervention."	2.73	Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. ( Arruda, M; Barrett, C; Beheiry, S; Cummings, J; Di Biase, L; Fahmy, T; Hao, S; Kanj, M; Martin, DO; Natale, A; Patel, D; Saliba, W; Schweikert, R; Wazni, OM, 2007)
"Patients with stroke are at substantial risk of thromboembolic complications and therefore require antithrombotic prophylaxis."	2.72	Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. ( Brom, J; Csányi, A; Diener, HC; Harenberg, J; Klingelhöfer, J; Koppenhagen, K; Landgraf, H; Rektor, I; Ringelstein, EB; Schneider, D; von Kummer, R; Weidinger, G, 2006)
"Bleeding was similar with all dosing strategies in patients with adequate renal function and appeared to be more frequent in those with renal impairment."	2.71	Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. ( Adamson, R; Khazan, M; Mathis, AS; Scheuering, S, 2003)
"More bleeding was observed with enoxaparin, with a statistically significant increase in TIMI (Thrombolysis in Myocardial Infarction) major bleeding (9."	2.71	Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. ( Antman, EM; Armstrong, PW; Avezum, A; Aylward, P; Becker, RC; Biasucci, L; Borzak, S; Califf, RM; Cohen, M; Col, J; Ferguson, JJ; Frey, MJ; Fry, E; Goodman, S; Grines, CL; Gulba, DC; Guneri, S; Gurfinkel, E; Harrington, R; Hochman, JS; Kereiakes, DJ; Kleiman, NS; Langer, A; Leon, MB; Lopez-Sendon, JL; Mahaffey, KW; Nessel, CC; Pepine, CJ; Ruzyllo, W; Steinhubl, SR; Teirstein, PS; Toro-Figueroa, L; White, H, 2004)
" dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH."	2.70	Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002)
"Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio."	2.61	Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019)
"The antiphospholipid syndrome is described with a review of its historical development as a recognized syndrome, what constitutes an antiphospholipid antibody, how it is measured, and how the syndrome is treated."	2.43	The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it? ( Ortel, TL, 2006)
" Here we describe the results of 3 studies that evaluated the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects."	1.56	Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. ( Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)
"Aspirin (53."	1.43	Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016)
"Dabigatran has demonstrated similar efficacy and safety to enoxaparin for VTE prevention in patients undergoing hip and knee arthroplasty, and to warfarin for the treatment of VTE."	1.42	The evolving role of dabigatran etexilate in clinical practice. ( Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA, 2015)
"Systemic thromboembolism is a severe complication in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF)."	1.37	Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. ( Alberti, S; Angeloni, G; Banzato, A; Cucchini, U; Formichi, M; Pengo, V; Romagnoli, E, 2011)
" The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin."	1.35	ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. ( Giugliano, RP; Thomas, D, 2009)
"The stroke was diagnosed on magnetic resonance imaging."	1.35	An acute ischemic stroke secondary to sphenoid sinusitis. ( Bessou, P; Bing, F; Boubagra, K; Reyt, E; Righini, CA, 2009)
"Drugs approved and used for treatment of stroke vary from country to country."	1.35	Publication bias perpetuates use of ineffective drugs in stroke. ( Prasad, K, 2009)
"Thus clinical application of enoxaparin treatment in stroke warrants serious consideration."	1.31	Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. ( Mary, V; Stutzmann, JM; Uzan, A; Wahl, F, 2001)

Research

Studies (99)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

mITT Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (2.02)	18.2507
2000's	57 (57.58)	29.6817
2010's	34 (34.34)	24.3611
2020's	6 (6.06)	2.80

Authors	Studies
Dluha, J	1
Sivak, S	1
Kurca, E	1
Dusenka, R	1
Kalmarova, K	1
Turcanova Koprusakova, M	1
Kantorova, E	1
Nosal, V	1
Prasad, K	1
Bang, OY	1
Kim, JS	1
Wang, QS	1
Chen, C	2
Chen, XY	1
Han, JH	1
Soo, Y	1
Leung, TW	1
Mok, V	1
Wong, KS	2
Sarma, GR	1
Roy, AK	1
Kumar, S	1
Ng, PW	1
Tsoi, TH	1
Li, HL	1
Fong, WC	1
Yeung, J	1
Wong, CK	1
Yip, KK	1
Gao, H	1
Wong, HB	1
Wong, JS	1
Dechambre, S	1
Duprez, T	1
Cosnard, G	1
Angeloni, G	1
Alberti, S	1
Romagnoli, E	1
Banzato, A	1
Formichi, M	1
Cucchini, U	1
Pengo, V	1
Dawwas, GK	1
Cuker, A	1
Rothstein, A	1
Hennessy, S	1
Yasutaka, Y	1
Fujioka, S	1
Tsuboi, Y	1
Oyabu, K	1
Shibaguchi, H	1
Kamimura, H	1
Limsakun, T	1
Dishy, V	1
Mendell, J	1
Pizzagalli, F	1
Pav, J	1
Kochan, J	1
Vandell, AG	1
Rambaran, C	1
Kobayashi, F	1
Orihashi, Y	1
Warren, V	1
McPhillips, P	1
Zhou, J	1
Kozieł, M	1
Merino, JL	2
De Caterina, R	1
Huber, K	1
Jin, J	2
Melino, M	2
Goette, A	3
Lip, GYH	1
Sierra-Hidalgo, F	1
Muñoz-Rivas, N	1
Torres Rubio, P	1
Chao, K	1
Villanova Martínez, M	1
Arranz García, P	1
Martínez-Acebes, E	1
Oh, HJ	1
Ryu, KH	1
Park, BJ	1
Yoon, BH	1
Perry, LA	1
Berge, E	2
Bowditch, J	1
Forfang, E	1
Rønning, OM	1
Hankey, GJ	2
Villanueva, E	1
Al-Shahi Salman, R	1
Nam, KW	1
Kim, CK	1
Kim, TJ	1
An, SJ	1
Oh, K	1
Ko, SB	1
Yoon, BW	1
Chi, G	3
Januzzi, JL	1
Korjian, S	3
Daaboul, Y	3
Goldhaber, SZ	3
Hernandez, AF	3
Hull, RD	3
Gold, A	2
Cohen, AT	5
Harrington, RA	3
Gibson, CM	3
Navi, BB	1
Marshall, RS	1
Bobrow, D	1
Singer, S	1
Stone, JB	1
DeSancho, MT	1
DeAngelis, LM	1
Benatta, NF	1
Batouche, DD	1
Djazouli, MA	1
Miller, KM	1
Brenner, MJ	1
Nafee, T	1
Yee, MK	1
Kerneis, M	1
Kalayci, A	1
Afzal, MK	1
Kazmi, H	1
Datta, S	1
AlKhalfan, F	1
Klein, HH	1
Clemens, A	1
Fraessdorf, M	1
Friedman, J	1
Darwish, OS	1
Strube, S	1
Nguyen, HM	1
Tanios, MA	1
Roberts, A	1
Yi, X	1
Lin, J	3
Wang, C	1
Zhang, B	1
Chi, W	1
Sengupta, N	1
Feuerstein, JD	1
Patwardhan, VR	1
Tapper, EB	1
Ketwaroo, GA	1
Thaker, AM	1
Leffler, DA	1
Hellenbart, E	1
Drambarean, B	1
Lee, J	1
Nutescu, EA	1
Azab, SF	1
Akeel, NE	1
Abdalhady, MA	1
Elhewala, AA	1
Ali, ASA	1
Amin, EK	1
Sarhan, DT	1
Almalky, MAA	1
Elhindawy, EM	1
Salam, MMA	1
Soliman, AA	1
Abdellatif, SH	1
Ismail, SM	1
Elsamad, NA	1
Hashem, MIA	1
Aziz, KA	1
Elazouni, OMA	1
Arafat, MS	1
Mitma, AA	1
Varghese, JG	1
Witt, D	1
Zarich, SW	1
Fahed, E	1
Ghauche, J	1
Rahme, R	1
Okais, N	1
Samaha, E	1
Nohra, G	1
Rizk, T	1
Maarrawi, J	1
Menassa-Moussa, L	1
Moussa, R	1
Ezekowitz, MD	1
Zamoryakhin, D	1
Mercuri, MF	1
Grosso, MA	1
Fernandez, V	1
Al-Saady, N	1
Pelekh, N	1
Merkely, B	1
Zenin, S	1
Kushnir, M	1
Spinar, J	1
Batushkin, V	1
de Groot, JR	1
Lip, GY	1
Raheemullah, A	1
Laurence, TN	1
Lui, JK	1
McIntosh, LJ	1
Escobar Valle, J	1
Stockl, T	1
Summers, S	1
Halaby, R	1
Jain, P	1
Arbetter, D	1
Hull, R	1
Bandman, O	1
Budaj, A	3
Eikelboom, JW	2
Mehta, SR	4
Afzal, R	3
Chrolavicius, S	3
Bassand, JP	3
Fox, KA	3
Wallentin, L	5
Peters, RJ	2
Granger, CB	3
Joyner, CD	1
Yusuf, S	4
Thomas, D	1
Giugliano, RP	1
Boden, WE	1
Flather, M	1
Steg, PG	1
Avezum, A	2
Piegas, LS	1
Faxon, DP	1
Widimsky, P	1
Rupprecht, HJ	1
Jolly, S	1
Hart, RG	1
Kase, CS	1
Albers, GW	1
Bladin, C	1
Fieschi, C	1
Gabbai, AA	1
O'Riordan, W	1
Pineo, GF	1
Dobrev, D	1
Ravens, U	1
Chilukuri, K	1
Mayer, SA	1
Scherr, D	1
Dalal, D	1
Abraham, T	1
Henrikson, CA	1
Cheng, A	1
Nazarian, S	1
Sinha, S	1
Spragg, D	1
Berger, R	1
Calkins, H	1
Marine, JE	1
Pineo, G	2
Stern, L	2
Subrahmanian, T	2
Annemans, L	2
Broderick, PA	1
Kolodny, EH	1
Turpie, AG	3
Schellong, SM	1
Tapson, VF	1
Monreal, M	1
Samama, MM	1
Chen, M	1
Yusen, RD	1
Khazan, M	1
Scheuering, S	1
Adamson, R	1
Mathis, AS	1
Burak, CR	1
Bowen, MD	1
Barron, TF	1
Woessner, R	1
Grauer, M	1
Bianchi, O	1
Mueller, M	1
Moersdorf, S	1
Berlit, P	1
Goertler, M	1
Grotemeyer, KH	1
Sliwka, U	1
Stoll, M	1
Treib, J	1
Calvo-Romero, JM	1
Ferguson, JJ	2
Califf, RM	2
Antman, EM	1
Cohen, M	2
Grines, CL	1
Goodman, S	1
Kereiakes, DJ	1
Langer, A	2
Mahaffey, KW	2
Nessel, CC	1
Armstrong, PW	1
Aylward, P	1
Becker, RC	1
Biasucci, L	1
Borzak, S	1
Col, J	1
Frey, MJ	1
Fry, E	1
Gulba, DC	1
Guneri, S	1
Gurfinkel, E	1
Harrington, R	1
Hochman, JS	1
Kleiman, NS	2
Leon, MB	1
Lopez-Sendon, JL	1
Pepine, CJ	1
Ruzyllo, W	1
Steinhubl, SR	1
Teirstein, PS	1
Toro-Figueroa, L	1
White, H	1
Jaffer, AK	1
Ahmed, M	1
Brotman, DJ	1
Bragg, L	1
Seshadri, N	1
Qadeer, MA	1
Klein, A	1
Garg, J	1
Antman, E	1
Goodman, SG	1
Berdan, LG	1
Reist, CJ	1
White, HD	1
Aylward, PE	1
Col, JJ	1
Ortel, TL	2
Pogue, J	1
Joyner, C	1
Alli, NA	1
Wainwright, RD	1
Mackinnon, D	1
Poyiadjis, S	1
Naidu, G	1
Quartermain, D	1
Li, YS	1
Jonas, S	1
Shammas, NW	1
Dippel, EJ	1
Harb, G	1
Egts, S	1
Jerin, M	1
Stoakes, P	1
Byrd, J	1
Shammas, GA	1
Sharis, P	1
Wazni, OM	1
Beheiry, S	1
Fahmy, T	1
Barrett, C	1
Hao, S	1
Patel, D	1
Di Biase, L	1
Martin, DO	1
Kanj, M	1
Arruda, M	1
Cummings, J	1
Schweikert, R	1
Saliba, W	1
Natale, A	1
Drossbach, M	1
Karaaslan, P	1
Pirat, A	1
Karakayali, H	1
Can, U	1
Arslan, G	1
Assadian, A	1
Knöbl, P	1
Hübl, W	1
Senekowitsch, C	1
Klingler, A	1
Pfaffelmeyer, N	1
Hagmüller, GW	1
Smoot, EC	1
Muir, KW	1
Mary, V	2
Wahl, F	2
Uzan, A	2
Stutzmann, JM	2
Alikhan, R	1
Grosjean-Piot, O	1
Pratt, J	1
Hillbom, M	1
Erilä, T	1
Sotaniemi, K	1
Tatlisumak, T	1
Sarna, S	1
Kaste, M	1
Counsell, C	1
Sandercock, P	1
Xie, C	1
Ahmed, RJ	1
Xavier, D	1
Pais, P	1
Zhu, J	1
Liu, L	1
Diener, HC	2
Ringelstein, EB	8
von Kummer, R	2
Landgraf, H	2
Koppenhagen, K	1
Harenberg, J	1
Rektor, I	1
Csányi, A	1
Schneider, D	1
Klingelhöfer, J	1
Brom, J	2
Weidinger, G	2
Langohr, HD	1
Bewermeyer, H	1
Hennerici, M	1
Welzel, D	1
Gräve, M	1
Clark, NP	1
Douketis, JD	1
Hasselblad, V	1
Schulman, S	1
Kindzelski, AL	1
McMahon, GS	1
Webster, SE	1
Hayes, PD	1
Jones, CI	1
Goodall, AH	1
Naylor, AR	1
Righini, CA	1
Bing, F	1
Bessou, P	1
Boubagra, K	1
Reyt, E	1
Husted, SE	2
Lagerqvist, B	1
Kontny, F	2
Ståhle, E	1
Swahn, E	1
James, S	1
Armstrong, P	1
Califf, R	1
Husted, S	1
Niemminen, M	1
Pfisterer, M	1
Simoons, ML	1
Zeuthen, EL	1
Lassen, JF	1
Abdelnoor, M	1
Nakstad, PH	1
Sandset, PM	1
Pereira, AC	1
Warburton, E	1
Adams, HP	1
Sare, GM	2
Bath, PM	9
Gray, LJ	5
Moulin, T	3
Woimant, F	3
England, T	2
Geeganage, C	3
Christensen, H	4
De Deyn, PP	6
Leys, D	8
O'Neill, D	8
England, TJ	1
De Deyn, P	2
Tracy, M	1
Sare, G	1
Sprigg, N	4
Boysen, G	4
Friis, P	3
Marttila, R	3
Olsson, JE	2
Ringelstein, B	2
van der Sande, JJ	2
Lindenstrøm, E	2
Lindenstrom, E	1
Olsson, J	1
Orgogozo, J	1
van der Sande, J	1
Chamorro, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke[NCT01862978]	Phase 4	150 participants (Anticipated)	Interventional	2013-05-31	Recruiting
A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects[NCT02560688]	Phase 1	22 participants (Actual)	Interventional	2015-12-31	Completed
A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS[NCT02071004]	Phase 1	18 participants (Actual)	Interventional	2014-01-31	Completed
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218]	Phase 3	7,513 participants (Actual)	Interventional	2012-03-31	Completed
A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial F[NCT02072434]	Phase 3	2,199 participants (Actual)	Interventional	2014-03-25	Completed
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287]	Phase 2	80 participants (Anticipated)	Interventional	2014-01-31	Recruiting
An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke[NCT00077805]	Phase 4	0 participants	Interventional	2003-08-31	Completed
A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization[NCT00077753]	Phase 4	4,726 participants	Interventional	2002-02-28	Completed
A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784]	Phase 3	8,000 participants	Interventional	2001-08-31	Completed
Genetics of Antiphospholipid Antibody Syndrome[NCT00482794]		2,800 participants (Anticipated)	Observational	2006-06-30	Recruiting
An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes[NCT00139815]	Phase 3	20,078 participants (Actual)	Interventional	2003-04-30	Completed
Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine[NCT04507178]	Phase 2	100 participants (Anticipated)	Interventional	2022-02-02	Recruiting
Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke[NCT00836355]		6 participants (Actual)	Interventional	2009-04-30	Terminated (stopped due to Too few acute stroke patients available to meet enrollment requirements.)
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349]	Phase 4	105 participants (Actual)	Interventional	2012-05-31	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)

mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

Intervention	Percentage of Participants (Number)
Betrixaban	1.30
Enoxaparin	1.90

mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)

mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

Intervention	Percentage of Participants (Number)
Betrixaban	1.03
Enoxaparin	1.45

mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)

mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

Intervention	Percentage of Participants (Number)
Betrixaban	4.70
Enoxaparin	6.02

mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)

mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

Intervention	Percentage of Participants (Number)
Betrixaban	0.94
Enoxaparin	1.45

mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)

Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

Intervention	Percentage of Participants (Number)
Betrixaban	4.43
Enoxaparin	5.99

mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)

Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication

Intervention	Percentage of Participants (Number)
Betrixaban	5.70
Enoxaparin	7.18

Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)

Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From Randomization to End of Follow up

Percentage of Participants With Composite Endpoints of Major and Clinically-relevant Non-major (CRNM) Bleeding

Percentage of Participants With Composite Endpoints of Stroke, SEE, MI, CV Mortality, and Major Bleeding

Intervention	Percentage of Participants (Number)
Betrixaban	0.67
Enoxaparin	0.57

Intervention	Percentage of participants (Number)
Edoxaban	0.5
Warfarin	1

Intervention	Percentage of participants (Number)
Edoxaban	1.5
Warfarin	1

(NCT02072434)
Timeframe: From randomization to the end of follow-up (within 2 years)

Article	Year
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. Medicine, 2021, Mar-19, Volume: 100, Issue:11 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Fema	2021
Antithrombotic treatment after stroke due to intracerebral haemorrhage. The Cochrane database of systematic reviews, 2017, 05-25, Volume: 5 Topics: Cerebral Hemorrhage; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Intracranial Thrombosis; Rand	2017
Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. Drugs, 2019, Volume: 79, Issue:3 Topics: Anticoagulants; Benzamides; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage;	2019
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S	2013
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vascular health and risk management, 2013, Volume: 9 Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution	2013
What's new in stroke? The top 10 studies of 2006-2008. Part II. Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:12 Topics: Anticoagulants; Atorvastatin; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrin	2008
Discoveries in thrombosis care for medical patients. Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3 Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Critical Care; Drug Costs; Enoxaparin; Fibrinolytic	2002
The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it? Journal of thrombosis and thrombolysis, 2006, Volume: 21, Issue:1 Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; beta 2-Glycoprotein I	2006
Skull bone infarctive crisis and deep vein thrombosis in homozygous sickle cell disease- case report and review of the literature. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:2 Topics: Anemia, Sickle Cell; Anticoagulants; Catheterization; Child; Diagnosis, Differential; Edema; Enoxapa	2007
Prophylaxis of venous thromboembolism in medical patients. Current opinion in pulmonary medicine, 2001, Volume: 7, Issue:5 Topics: Anticoagulants; Bandages; Brain Ischemia; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Myocard	2001
Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS drug reviews, 2002,Spring, Volume: 8, Issue:1 Topics: Animals; Anticoagulants; Brain Edema; Brain Injuries; Brain Ischemia; Cognition Disorders; Enoxapari	2002
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review). Stroke, 2002, Volume: 33, Issue:7 Topics: Acute Disease; Anticoagulants; Brain Ischemia; Chondroitin Sulfates; Databases, Factual; Dermatan Su	2002
Long-term management--the way forward? Clinical cardiology, 2000, Volume: 23 Suppl 1 Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin	2000

Article	Year
Publication bias perpetuates use of ineffective drugs in stroke. International journal of stroke : official journal of the International Stroke Society, 2009, Volume: 4, Issue:3 Topics: Fibrinolytic Agents; Humans; Nadroparin; Nootropic Agents; Piracetam; Publication Bias; Research Des	2009
Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants? Stroke, 2012, Volume: 43, Issue:2 Topics: Antifibrinolytic Agents; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Female; Humans; Intra	2012
Nadroparin in acute ischemic stroke. Neurology India, 2004, Volume: 52, Issue:2 Topics: Anticoagulants; Brain Ischemia; Humans; Nadroparin; Stroke	2004
Spontaneous suprachoroidal haemorrhage in a patient receiving low-molecular-weight heparin (fraxiparine) therapy. Australian and New Zealand journal of ophthalmology, 1999, Volume: 27, Issue:6 Topics: Aged; Anticoagulants; Choroid Hemorrhage; Humans; Injections, Subcutaneous; Male; Nadroparin; Stroke	1999
Images in clinical radiology. Updated MR work-up of hyperacute stroke. JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR), 1999, Volume: 82, Issue:1 Topics: Aspirin; Echo-Planar Imaging; Fibrinolytic Agents; Humans; Image Enhancement; Infarction, Anterior C	1999
Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. Internal and emergency medicine, 2011, Volume: 6, Issue:2 Topics: Aged; Anticoagulants; Atrial Fibrillation; Confidence Intervals; Electric Countershock; Female; Hepa	2011
Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022, Volume: 31, Issue:10 Topics: Aftercare; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dalteparin; Enoxaparin; Hep	2022
Liver toxicity of intravenous heparin treatment in patients with acute ischemic stroke. Clinical neurology and neurosurgery, 2023, Volume: 226 Topics: Anticoagulants; Cerebral Infarction; Edaravone; Enoxaparin; Heparin; Humans; Ischemic Stroke; Liver;	2023
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Journal of clinical pharmacology, 2020, Volume: 60, Issue:6 Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P	2020
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Journal of clinical pharmacology, 2020, Volume: 60, Issue:6 Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P	2020
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Journal of clinical pharmacology, 2020, Volume: 60, Issue:6 Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P	2020
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Journal of clinical pharmacology, 2020, Volume: 60, Issue:6 Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P	2020
Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. European journal of clinical investigation, 2020, Volume: 50, Issue:5 Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clinical Decision-Making; Duration of T	2020
Large artery ischemic stroke in severe COVID-19. Journal of neurology, 2020, Volume: 267, Issue:12 Topics: Aged; Brain Ischemia; Cerebral Arteries; Computed Tomography Angiography; Coronavirus Infections; CO	2020
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:12 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Daltep	2017
[Anticoagulation's problematic during pregnancy in carriers of mechanical heart prosthesis]. Annales de cardiologie et d'angeiologie, 2018, Volume: 67, Issue:4 Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Algeria; Anticoagulants; Enoxaparin; Female; Heart Valv	2018
Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation, 2019, 02-26, Volume: 139, Issue:9 Topics: Benzamides; Enoxaparin; Female; Humans; Male; Myocardial Infarction; Pyridines; Risk Factors; Stroke	2019
Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:10 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heparin; Humans; I	2013
Anticoagulation therapy: Edoxaban noninferior to warfarin in patients with AF. Nature reviews. Cardiology, 2014, Volume: 11, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Embolism; Enoxaparin; Female; Humans; Male; Stroke; Warfarin	2014
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. The American journal of gastroenterology, 2015, Volume: 110, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E	2015
The evolving role of dabigatran etexilate in clinical practice. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13 Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinic	2015
Serum Hepcidin Levels in Childhood-Onset Ischemic Stroke: A Case-Control Study. Medicine, 2016, Volume: 95, Issue:9 Topics: Acute Disease; Adolescent; Brain Ischemia; Child; Child, Preschool; Enoxaparin; Enzyme-Linked Immuno	2016
Stroke and a valvular lesion in a patient with stage IV non-small cell lung cancer. BMJ case reports, 2016, May-31, Volume: 2016 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Anticoagulants; Cerebellum; Diagnosis, Differential; E	2016
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. World neurosurgery, 2016, Volume: 95 Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra	2016
Repeated Thrombosis After Synthetic Cannabinoid Use. The Journal of emergency medicine, 2016, Volume: 51, Issue:5 Topics: Adult; Anticoagulants; Aspirin; Cannabinoids; Enoxaparin; Female; Humans; Infarction; Platelet Aggre	2016
Facial Drooping, Aphasia, and an Incidental Lung Mass in a Nonsmoker. Journal of intensive care medicine, 2017, Volume: 32, Issue:3 Topics: Aged; Air Pollutants, Occupational; Anticoagulants; Aphasia; Atrial Flutter; Carcinoma, Squamous Cel	2017
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation, 2017, 02-14, Volume: 135, Issue:7 Topics: Aged; Anticoagulants; Benzamides; Enoxaparin; Female; Humans; Male; Pyridines; Stroke; Venous Thromb	2017
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:1 Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Dr	2009
Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery. Cardiovascular therapeutics, 2009,Winter, Volume: 27, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Enoxaparin; Hemorrhage; Humans; Stroke; Vitamin K	2009
Transoesophageal echocardiography predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2010, Volume: 12, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Catheter Ablation; Echocardiography	2010
Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011, Volume: 17, Issue:2 Topics: Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Child; Costs and Cost Analysis; Decision Ma	2011
Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial. Journal of hospital medicine, 2012, Volume: 7, Issue:3 Topics: Acute Disease; Anticoagulants; Cost Savings; Cost-Benefit Analysis; Databases, Factual; Decision Sup	2012
Biosensors for brain trauma and dual laser doppler flowmetry: enoxaparin simultaneously reduces stroke-induced dopamine and blood flow while enhancing serotonin and blood flow in motor neurons of brain, in vivo. Sensors (Basel, Switzerland), 2011, Volume: 11, Issue:1 Topics: Animals; Anticoagulants; Biosensing Techniques; Blood Flow Velocity; Brain Injuries; Dopamine; Elect	2011
The use of enoxaparin in children with acute, nonhemorrhagic ischemic stroke. Pediatric neurology, 2003, Volume: 29, Issue:4 Topics: Adolescent; Child; Child, Preschool; Enoxaparin; Female; Humans; Male; Retrospective Studies; Stroke	2003
Hemorrhagic transformation of ischemic stroke associated with enoxaparin and aspirin concomitant therapy. Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:1 Topics: Acute Disease; Anticoagulants; Aspirin; Cerebral Hemorrhage; Drug Therapy, Combination; Enoxaparin;	2004
Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. Journal of thrombosis and thrombolysis, 2005, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heart Valve	2005
[Stroke with leg paralysis -- cardioversion in atrial fibrillation: prevention of thromboembolism in risk patients]. MMW Fortschritte der Medizin, 2006, Jun-08, Volume: 148, Issue:23 Topics: Administration, Oral; Age Factors; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation	2006
Acute enoxaparin treatment widens the therapeutic window for tPA in a mouse model of embolic stroke. Neurological research, 2007, Volume: 29, Issue:5 Topics: Animals; Behavior, Animal; Brain Infarction; Disease Models, Animal; Drug Interactions; Enoxaparin;	2007
Interatrial septal defect closure for cerebrovascular accidents: exploring the role of various anticoagulants. The Journal of invasive cardiology, 2007, Volume: 19, Issue:7 Topics: Anticoagulants; Antithrombins; Cardiac Surgical Procedures; Enoxaparin; Female; Follow-Up Studies; H	2007
[Stroke. Enoxaparin sodium inhibits venous thromboembolism compared to unfractionated heparin]. Medizinische Monatsschrift fur Pharmazeuten, 2007, Volume: 30, Issue:11 Topics: Anticoagulants; Enoxaparin; Heparin; Humans; Randomized Controlled Trials as Topic; Stroke; Thromboe	2007
Bilateral thalamic infarct after general anaesthesia for laparotomy: an unusual case of perioperative cryptogenic stroke. Acta anaesthesiologica Scandinavica, 2008, Volume: 52, Issue:2 Topics: Adult; Anesthesia, General; Anticoagulants; Blood Loss, Surgical; Enoxaparin; Female; Humans; Infarc	2008
Withholding warfarin therapy for atrial fibrillation patients in the perioperative period. Plastic and reconstructive surgery, 2008, Volume: 121, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enoxaparin; Humans; Perioperative Care; Stroke;	2008
The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism. Stroke, 2008, Volume: 39, Issue:7 Topics: Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation In	2008
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. Stroke, 2001, Volume: 32, Issue:4 Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa	2001
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. Stroke, 2001, Volume: 32, Issue:4 Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa	2001
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. Stroke, 2001, Volume: 32, Issue:4 Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa	2001
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. Stroke, 2001, Volume: 32, Issue:4 Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa	2001
[When ASS, when anticoagulants?]. MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Clopidogrel; Female; Heart Disease	2006
An acute ischemic stroke secondary to sphenoid sinusitis. Ear, nose, & throat journal, 2009, Volume: 88, Issue:11 Topics: Acute Disease; Acyclovir; Adult; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Carotid Ar	2009
Heparin vs aspirin in acute ischaemic stroke. Lancet (London, England), 2000, Jul-01, Volume: 356, Issue:9223 Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dalteparin; Dose-Response Relationship, Drug; Hum	2000
Antiplatelet aggregating versus anticoagulant agents in preventing early recurrent stroke among patients with atrial fibrillation. Current neurology and neuroscience reports, 2001, Volume: 1, Issue:1 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Dalteparin; Platelet Aggrega	2001
Atrial fibrillation, stroke, and acute antithrombotic therapy. Stroke, 2003, Volume: 34, Issue:3 Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Randomized	2003
New drugs, or new trials of current drugs, for the treatment of acute ischaemic stroke? Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283 Topics: Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Stroke; Tinzaparin	2001
Early anticoagulation in acute ischaemic stroke. Lancet (London, England), 2002, Feb-09, Volume: 359, Issue:9305 Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Strok	2002

dalteparin and Stroke